البروفيسور ريكاردو روساتي هو رئيس قسم جراحة الجهاز الهضمي (GI) في مستشفى أبحاث سان رافاييل في ميلانو ، إيطاليا. إنه جراح ذو خبرة عالية مع أكثر من 30 عامًا من الخبرة ، وحصل على درجات طبية في الطب العام والجراحة العامة ، وكذلك تخصص في جراحة الصدر. وهو عضو في عدة جمعيات جراحية ، وله أكثر من 300 منشور. يعالج قسمه ما يقرب من 2000 حالة جراحية سنويًا.
اقرأ المزيدالبروفيسور ريكاردو روساتي هو رئيس قسم جراحة الجهاز الهضمي (GI) في مستشفى أبحاث سان رافاييل في ميلانو ، إيطاليا. إنه جراح ذو خبرة عالية مع أكثر من 30 عامًا من الخبرة ، وحصل على درجات طبية في الطب العام والجراحة العامة ، وكذلك تخصص في جراحة الصدر. وهو عضو في عدة جمعيات جراحية ، وله أكثر من 300 منشور. يعالج قسمه ما يقرب من 2000 حالة جراحية سنويًا.
Prof. Andrea Lania has graduated at the Università degli Studi of Milan and is specialized in endocrinology. He is the Unit Director of Endocrinology and Diabetology in Humanitas Research Hospital and his specialization is pituitary diseases, pituitary adenomas, thyroid cancer, pancreatic neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas.
Medical areas of interest:
Pituitary tumors, hypopituitarism, acromegaly, Cushing’s disease and syndrome, neuroendocrine tumors, thyroid and thyroid diseases, adrenal and adrenal diseases, hypogonadism.
Research areas of interest:
Study of the pathogenetic mechanisms of pituitary and neuroendocrine tumors, of the molecular mechanisms responsible for the different response of pituitary and neuroendocrine tumors to medical therapy.
Prof. Lania published 198 peer-reviewed papers (Google Scholar H-Index 47; Scopus H-Index 38, cit tot 4604)
Prof. Lania has a long standing expertise in the field of intra-cellular signaling in endocrine tumors. In particular, in the past ten years, he contributed to analyze the role of PKA regulatory subunits in the pathogenesis and control of cell proliferation of endocrine tumors. Moreover, he contributed to define the role of SSTR5 domains involved in the intracellular trafficking of this receptor in human pituitary cells and to analyze the impact of DR2R and SSTR2&5 polymorphic variants on both the clinical outcome and response to medical treatment in patients with pituitary tumors.
Recently, he contributed to identify the role of cytoskeleton protein FLNA in mediating both intracellular signaling and membrane targeting of somatostatin type 2 receptor and D2R in pituitary and pancreatic neuroendocrine tumors. Finally, he contributed to explore the intracellular mechanisms possibly involved in mediating the interplay between drugs commonly used in the treatment of neuroendocrine tumors.
Previous experience:
2005-2008 Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy
Director of Endocrinologic Day Hospital and surgery on pituitary disorders.
Publications: https://www.ncbi.nlm.nih.gov/pubmed?term=lania%20A
اقرأ المزيدProf. Andrea Lania has graduated at the Università degli Studi of Milan and is specialized in endocrinology. He is the Unit Director of Endocrinology and Diabetology in Humanitas Research Hospital and his specialization is pituitary diseases, pituitary adenomas, thyroid cancer, pancreatic neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas.
Medical areas of interest:
Pituitary tumors, hypopituitarism, acromegaly, Cushing’s disease and syndrome, neuroendocrine tumors, thyroid and thyroid diseases, adrenal and adrenal diseases, hypogonadism.
Research areas of interest:
Study of the pathogenetic mechanisms of pituitary and neuroendocrine tumors, of the molecular mechanisms responsible for the different response of pituitary and neuroendocrine tumors to medical therapy.
Prof. Lania published 198 peer-reviewed papers (Google Scholar H-Index 47; Scopus H-Index 38, cit tot 4604)
Prof. Lania has a long standing expertise in the field of intra-cellular signaling in endocrine tumors. In particular, in the past ten years, he contributed to analyze the role of PKA regulatory subunits in the pathogenesis and control of cell proliferation of endocrine tumors. Moreover, he contributed to define the role of SSTR5 domains involved in the intracellular trafficking of this receptor in human pituitary cells and to analyze the impact of DR2R and SSTR2&5 polymorphic variants on both the clinical outcome and response to medical treatment in patients with pituitary tumors.
Recently, he contributed to identify the role of cytoskeleton protein FLNA in mediating both intracellular signaling and membrane targeting of somatostatin type 2 receptor and D2R in pituitary and pancreatic neuroendocrine tumors. Finally, he contributed to explore the intracellular mechanisms possibly involved in mediating the interplay between drugs commonly used in the treatment of neuroendocrine tumors.
Previous experience:
2005-2008 Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy
Director of Endocrinologic Day Hospital and surgery on pituitary disorders.
Publications: https://www.ncbi.nlm.nih.gov/pubmed?term=lania%20A